TARGETING NUCLEOLAR DNA DAMAGE RESPONSE AS A NOVEL THERAPEUTIC STRATEGY FOR HIGH GRADE SEROUS OVARIAN CANCER
Grant number: 1162052 | Funding period: 2019 - 2022
This grant will provide supplemental funding to the fall 2012 Thematic Program on Forcing and its Applications at the Fields Institute in Toronto, Ontario. Fifty years ago Paul Cohen developed the method of forcing to solve Hilbert's first problem: the truth of the Continuum Hypothesis. Today this method is more relevant than ever. While it was originally developed as a meta-mathematical tool, it has been also used to solve problems arising in combinatorics, functional analysis, and topology. As the method matured and became even more powerful, its scope and reach has been significantly broadened. New directions in forcing are ever more influenced by fundamental questions in a broadening ran..View full description
Related publications (5)
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Jian Kang, Natalie Brajanovski, Keefe T Chan, Jiachen Xuan, Richard B Pearson, Elaine Sanij
Ribosome biogenesis and protein synthesis are fundamental rate-limiting steps for cell growth and proliferation. The ribosomal pro..
rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
Jinbae Son, Katherine M Hannan, Gretchen Poortinga, Nadine Hein, Donald P Cameron, Austen RD Ganley, Karen E Sheppard, Richard B Pearson, Ross D Hannan, Elaine Sanij
Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and ..
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna
Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..